Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors

European Cells and Materials

Volumn 26, Issue , 2013, Pages 66-79

  Grote, K ^a   Petri, M ^a   Liu, C ^a   Jehn, P ^a   Spalthoff, S ^a   Kokemuller H ^a   Luchtefeld, M ^a   Tschernig, T ^b   Krettek, C ^a   Haasper, C ^a   Jagodzinski, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Growth factors; Mesenchymal stem cells; Tissue engineering; Toll like receptors

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; ILIAC CREST; IN VIVO STUDY; LATISSIMUS DORSI MUSCLE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SHEEP; TISSUE ENGINEERING;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPEPTIDES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; REGENERATION; SHEEP; TISSUE ENGINEERING; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6;

EID: 84884678089     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v026a05     Document Type: Article

References (40)

1. Armstrong L, Lako M, Buckley N, Lappin TR, Murphy MJ, Nolta JA, Pittenger M, Stojkovic M (2012) Editorial: Our top 10 developments in stem cell biology over the last 30 years. Stem Cells 30: 2-9.
2. Bancroft GN, Sikavitsas VI, van den Dolder J, Sheffield TL, Ambrose CG, Jansen JA, Mikos AG (2002) Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner. Proc Natl Acad Sci USA 99: 12600-12605.
3. Broese M, Toma I, Haasper C, Simon A, Petri M, Budde S, Wehmeier M, Krettek C, Jagodzinski M (2011) Seeding a human tendon matrix with bone marrow aspirates compared to previously isolated hBMSCs--an in vitro study. Technol Health Care 19: 469-479.
4. Brown J, Wang H, Hajishengallis GN, Martin M (2011) TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res 90: 417-427.
5. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR (2008) Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B-but not JNK-dependent mechanism. Am J Physiol Cell Physiol 294: C675-682.
6. Cuiffo BG, Karnoub AE (2012) Mesenchymal stem cells in tumor development: Emerging roles and concepts. Cell Adh Migr 6: 220-230.
7. Deiters U, Gumenscheimer M, Galanos C, Muehlradt PF (2003) Toll-like receptor 2-and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect Immun 71: 4456-4462.
8. Deiters U, Barsig J, Tawil B, Mühlradt PF (2004) The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice. Exp Dermatol 13: 731-739.
9. DelaRosa O, Lombardo E (2010) Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators Inflamm 2010: 865601.
10. Gómez-Barrena E, Rosset P, Müller I, Giordano R, Bunu C, Layrolle P, Konttinen YT, Luyten FP (2011) Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med 6: 1266-1286.
11. Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Mühlradt PF, Schieffer B (2010) Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood 115: 2543-2552.
12. Grote K, Sonnenschein K, Kapopara PR, Hillmer A, Grothusen C, Salguero G, Kotlarz D, Schuett H, Bavendiek U, Schieffer B (2013) Toll-like receptor 2/6 agonist macrophage-activating lipopeptide-2 promotes reendothelialization and unhibits neointima formation after vascular injury. Arterioscler Thromb Vasc Biol, in press.
13. Haasper C, Jagodzinski M, Drescher M, Meller R, Wehmeier M, Krettek C, Hesse E (2008) Cyclic strain induces FosB and initiates osteogenic differentiation of mesenchymal cells. Exp Toxicol Pathol 59: 355-363.
14. Hesse E, Kluge G, Atfi A, Correa D, Haasper C, Berding G, Shin HO, Viering J, Länger F, Vogt PM, Krettek C, Jagodzinski M (2010) Repair of a segmental long bone defect in human by implantation of a novel multiple disc graft. Bone 46: 1457-1463.
15. Jagodzinski M, Drescher M, Zeichen J, Hankemeier S, Krettek C, Bosch U, van Griensven M (2004) Effects of cyclic longitudinal mechanical strain and dexamethasone on osteogenic differentiation of human bone marrow stromal cells. Eur Cell Mater 7: 35-41.
16. Jagodzinski M, Breitbart A, Wehmeier M, Hesse E, Haasper C, Krettek C, Zeichen J, Hankemeier S (2008) Influence of perfusion and cyclic compression on proliferation and differentiation of bone marrow stromal cells in 3-dimensional culture. J Biomech 41: 1885-1891.
17. Kanczler JM, Oreffo RO (2008) Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 15: 100-114.
18. Kasper G, Dankert N, Tuischer J, Hoeft M, Gaber T, Glaeser JD, Zander D, Tschirschmann M, Thompson M, Matziolis G, Duda GN (2007) Mesenchymal stem cells regulate angiogenesis according to their mechanical environment. Stem Cells 25: 903-910.
19. Lei J, Wang Z, Hui D, Yu W, Zhou D, Xia W, Chen C, Zhang Q, Wang Z, Zhang Q, Xiang AP (2011) Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. Cell Immunol 271: 147-156.
20. Macedo L, Pinhal-Enfield G, Alshits V, Elson G, Cronstein BN, Leibovich SJ (2007) Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol 171: 1774-1788.
21. Mastri M, Shah Z, McLaughlin T, Greene CJ, Baum L, Suzuki G, Lee T (2012) Activation of Toll-like receptor 3 (TLR3) amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol 303: C1021-1033.
22. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
23. Muehlradt PF, Kiess M, Meyer H, Suessmuth R, Jung G (1997) Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185: 1951-1958.
24. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22: 377-384.
25. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR, Zipori D (2007) Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109: 1422-1432.
26. Piec G, Mirkovitch J, Palacio S, Mühlradt PF, Felix R (1999) Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro. Infect Immun 67: 6281-6285.
27. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
28. Rameshwar P (2012) Current thoughts on the therapeutic potential of stem cell. Methods Mol Biol 879: 3-26.
29. Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Muehlradt PF, Guzmán CA (2002) The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32: 2857-2865.
30. Schmidt J, Welsch T, Jäger D, Mühlradt PF, Büchler MW, Märten A (2007) Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 97: 598-604.
31. Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Mühlradt PF, Schmidt J, Märten A (2004) Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 53: 355-361.
32. Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, Akira S, Kishimoto T, Nakanishi K, Fujimoto J (2005) Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology 41: 443-450.
33. Taguchi T, Mitcham JL, Dower SK, Sims JE, Testa JR (1996) Chromosomal localization of TIL, a gene encoding a protein related to the Drosophila transmembrane receptor Toll, to human chromosome 4p14. Genomics 32: 486-488.
34. Takeda K, Kaisho T, Akira (2003) Toll-like receptors. Annu Rev Immunol 21: 335-376.
35. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muehlradt PF, Akira S (2000) Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol 164: 554-557.
36. Takeuchi O, Kawai T, Muehlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S (2001) Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13: 933-940.
37. Vemuri MC, Chase LG, Rao MS (2011) Mesenchymal stem cell assays and applications. Methods Mol Biol 698: 3-8.
38. Wang J, Liao L, Tan J (2011) Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin Biol Ther 11: 893-909.
39. Wu Y, Chen L, Scott PG, Tredget EE (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25: 2648-2659.
40. Yu L, Wang L, Chen S (2010) Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 14: 2592-2603.